Literature DB >> 27249715

Current State of Immune-Based Therapies for Glioblastoma.

Michael Lim1, Michael Weller1, E Antonio Chiocca1.   

Abstract

Glioblastoma is one of the most aggressive solid tumors, and, despite treatment options such as surgery, radiation, and chemotherapy, its prognosis remains grim. Novel approaches are needed to improve survival. Immunotherapy has proven efficacy for melanoma, lung cancer, and kidney cancer and is now a focus for glioblastoma. In this article, glioblastoma-mediated immunosuppression will be discussed and two exciting immune approaches, checkpoint inhibitors and viral-based therapies, will be reviewed.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27249715     DOI： 10.1200/EDBK_159084

Source DB:  PubMed          Journal:  Am Soc Clin Oncol Educ Book        ISSN： 1548-8748


  7 in total

1.  In search of a target: PD-1 and PD-L1 profiling across glioma types.

Authors:  Anna S Berghoff; Matthias Preusser
Journal:  Neuro Oncol       Date:  2016-08-17       Impact factor: 12.300

2.  Arming an Oncolytic Herpes Simplex Virus Type 1 with a Single-chain Fragment Variable Antibody against PD-1 for Experimental Glioblastoma Therapy.

Authors:  Carmela Passaro; Quazim Alayo; Isabella De Laura; John McNulty; Korneel Grauwet; Hirotaka Ito; Vivek Bhaskaran; Marco Mineo; Sean E Lawler; Khalid Shah; Maria C Speranza; William Goins; Eric McLaughlin; Soledad Fernandez; David A Reardon; Gordon J Freeman; E Antonio Chiocca; Hiroshi Nakashima
Journal:  Clin Cancer Res       Date:  2018-10-02       Impact factor: 12.531

Review 3.  Hitting the nail on the head: combining oncolytic adenovirus-mediated virotherapy and immunomodulation for the treatment of glioma.

Authors:  Wojciech K Panek; J Robert Kane; Jacob S Young; Aida Rashidi; Julius W Kim; Deepak Kanojia; Maciej S Lesniak
Journal:  Oncotarget       Date:  2017-09-11

4.  A nested case-control study of 277 prediagnostic serum cytokines and glioma.

Authors:  Judith Schwartzbaum; Min Wang; Elisabeth Root; Maciej Pietrzak; Grzegorz A Rempala; Ruo-Pan Huang; Tom Borge Johannesen; Tom K Grimsrud
Journal:  PLoS One       Date:  2017-06-08       Impact factor: 3.240

5.  Gene Polymorphisms Increasing the Risk of Intracranial Aneurysms: Interleukin-6 -174G>C and -572G>C (Part II).

Authors:  Alice Giotta Lucifero; Matias Baldoncini; Ilaria Brambilla; Monica Rutigliano; Gabriele Savioli; Renato Galzio; Alvaro Campero; Michael T Lawton; Sabino Luzzi
Journal:  Acta Biomed       Date:  2022-03-21

6.  Small molecules targeting histone demethylase genes (KDMs) inhibit growth of temozolomide-resistant glioblastoma cells.

Authors:  Barbara Banelli; Antonio Daga; Alessandra Forlani; Giorgio Allemanni; Daniela Marubbi; Maria Pia Pistillo; Aldo Profumo; Massimo Romani
Journal:  Oncotarget       Date:  2017-05-23

7.  Dendritic cell activation enhances anti-PD-1 mediated immunotherapy against glioblastoma.

Authors:  Tomas Garzon-Muvdi; Debebe Theodros; Andrew S Luksik; Russell Maxwell; Eileen Kim; Christopher M Jackson; Zineb Belcaid; Sudipto Ganguly; Betty Tyler; Henry Brem; Drew M Pardoll; Michael Lim
Journal:  Oncotarget       Date:  2018-04-17
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.